In partnership with EPP, Join Chad Gibson, EVERSANA’s Vice President for NAVLIN Consulting, in this informational webinar on “Empowering HTA in Europe: Unleashing the Potential of ITC, ECA & PROM Methods to Improve Access” on September 7, 2023 at 10am, EST.
Randomized controlled trials (RCT) with concrete clinical endpoints are the gold standard on the hierarchy of medical evidence. However, there are many circumstances where RCTs are not feasible to conduct, particularly for oncology and rare diseases, and ITC/ECA can be crucial to validating the value of a treatment. As well, concrete clinical endpoints in certain indications can be difficult to quantify and ultimately insufficient to truly demonstrate the impact of the treatment, leading to the need for support through patient reported outcome measures (PROM). In this webinar, we will discuss the growth in these alternate evidence methods, the receptiveness of the key HTA bodies through case studies and ultimately, what manufacturers can do to harness the power of these tools.
About Chad Gibson, Vice President, NAVLIN Consulting
Chad Gibson leads NAVLIN by EVERSANA’s consulting team focused on utilizing cutting-edge tools and expertise to deliver high quality, efficient market access consulting engagements.
Chad’s primary expertise is pricing and market access but also has experience in sales force/commercialization strategy, portfolio strategy, early-stage asset planning and business development. He has also worked in pricing strategy and analytics, access forecasting, contracting strategy, copay analytics, patient support benchmarking and account segmentation.
Prior to joining EVERSANA, Chad managed consulting engagements for Triangle Insights Group and worked with Syneos Health Consulting in pricing in market access. Chad received is MS in Business Analytics as well as a BS in Biological Sciences.